Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 25;9(11):e70256.
doi: 10.1002/hem3.70256. eCollection 2025 Nov.

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors

Romain Stammler  1 , Peter Chen  2 , Orianne Debeaupuis  2 , Lin-Pierre Zhao  3   4 , Mirabelle Ruyer-Thompson  1 , Eve Zakine  1 , Julien Rossignol  5 , Lauriane Goldwirt  6 , Thibault Comont  7   8   9 , Maël Heiblig  10 , Lionel Adès  3   4 , Marie Sebert  3   4 , Jean-Sébastien Allain  11 , Julien Campagne  12 , Marie-Anne Couturier  13 , Marina Cumin  14 , Marie-Caroline Dalmas  15 , Guillaume Denis  16 , Cécile Devloo  17 , Adrien De Voeght  18 , Louis Drevon  19 , Pierre Duffau  20 , Sophie Georgin-Lavialle  21 , Delphine Gobert  1 , Olivier Kosmider  22 , Frédéric Rieux-Laucat  2 , Noémie Abisror  1 , Estibaliz Lazaro  23 , Jean-Guillaume Lopez  24 , Alexandre Maria  25 , Wladimir Mauhin  26 , Julie Merindol  27 , Claire Merlot  28 , Tristan Mirault  29 , Laurent Pascal  30 , François Perrin  31 , Emmanuel Raffoux  32 , Ramy Rahme  33 , Damien Roos-Weil  34 , Benjamin Terrier  35 , Benjamin Thoreau  36 , Olivier Fain  1 , Pierre Fenaux  3   4 , Pierre Hirsch  37 , Vincent Jachiet  1 , Jérôme Hadjadj  1 , Arsène Mékinian  1 ; MINHEMON
Affiliations

Inflammatory disorders in IDH-mutated myeloid neoplasms: Characteristics and response to IDH inhibitors

Romain Stammler et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Cytokine profiling in immune‐mediated inflammatory disorder (IMID) patients with IDH mut or IDH wt myeloid neoplasms, and therapeutic efficacy of biotherapies and anti‐IDH inhibitors in IMID‐IDH mut patients. (A) Volcano plots showing upregulated (right) and downregulated (left) cytokines and chemokines between IDHmut and IDHwt. The green dashed line marks the significance threshold. Only significant cytokines are labeled. Global comparison of upregulated and downregulated cytokines between IDHmut and IDHwt groups. (B) Evolution of overall inflammatory response rates over time with biotherapies and azacitidine treatments. (C) Evolution of overall inflammatory response rates, steroid dosage, and C‐reactive protein level over time with IDH inhibitors. (D) Cytokine profile pre‐ and post‐ivosidenib (anti‐IDH1) in one patient showing log2 fold changes in circulating cytokines and chemokines, with upregulated (red) and downregulated (blue) markers. D‐2‐HG and C‐reactive protein (CRP) levels evolution under anti‐IDH1 inhibitor in the same patient. IL, interleukin‐6; TNF, tumor necrosis factor.
See this image and copyright information in PMC

References

    1. Adès L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet. 2014;383(9936):2239‐2252. - PubMed
    1. Komrokji RS, Kulasekararaj A, Al Ali NH, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016;91(5):E280‐E283. - PubMed
    1. Grignano E, Jachiet V, Fenaux P, Ades L, Fain O, Mekinian A. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018;97(11):2015‐2023. - PubMed
    1. Hochman MJ, DeZern AE. Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin? Lancet Haematol. 2022;9(7):e523‐e534. - PubMed
    1. Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in UBA1 and severe adult‐onset autoinflammatory disease. N Engl J Med. 2020;383(27):2628‐2638. - PMC - PubMed

LinkOut - more resources